Welcome to our dedicated page for MARSH & MCLENNAN COMPANIES SEC filings (Ticker: MRSH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on MARSH & MCLENNAN COMPANIES's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into MARSH & MCLENNAN COMPANIES's regulatory disclosures and financial reporting.
Marsh & McLennan Companies director Lloyd M. Yates sold 12000 shares of Common Stock on July 23, 2026 at $175.6500 per share in an open-market or private transaction. After this sale, he directly owned 12000.7500 shares, and the trade was not made under a Rule 10b5-1 plan.
MRSH filed a notice to sell up to 12,000 shares of common stock through Fidelity Brokerage Services LLC on the NYSE, with an aggregate market value of $2,107,826.07 as of the filing. The filing also lists the historical sources of these shares, including restricted stock vesting and an open market purchase between 2012 and 2015.
Marsh & McLennan Companies reported Q2 2026 revenue of $7,404 million, up from $6,974 million a year earlier. Net income attributable to the company was $1,266 million and diluted EPS was $2.63, compared with $1,211 million and $2.45.
For the first half of 2026, revenue was $15,001 million versus $14,035 million, while net income attributable declined to $2,412 million from $2,592 million as expenses, including $103 million of restructuring costs under the three‑year Thrive program, weighed on results. Operating cash flow was $835 million, down from $1,049 million.
At June 30, 2026, total assets were $59,682 million, cash and cash equivalents were $1,700 million plus $12,203 million held in a fiduciary capacity, and long‑term debt was $18,891 million. The company repurchased 8.7 million shares for $1.5 billion and paid dividends of $1.80 per share in the first half.
Marsh & McLennan Companies reported second-quarter 2026 revenue of $7.4 billion, up 6% year over year, or 5% on an underlying basis. Operating income rose 4% to $1.9 billion. Adjusted operating income increased 5% to $2.2 billion. GAAP EPS was $2.63 and adjusted EPS rose 9% to $2.96.
For the first six months of 2026, revenue was $15.0 billion, up 7% on a GAAP basis and 4% underlying. Operating income was $3.7 billion, down 5%, while adjusted operating income grew 7% to $4.6 billion. GAAP diluted EPS was $4.99 versus $5.23 a year earlier; adjusted EPS increased 8% to $6.25.
Risk & Insurance Services generated $4.8 billion of Q2 revenue, up 4% (3% underlying), and Consulting delivered $2.6 billion, up 10% (8% underlying). The company repurchased 4.5 million shares for $750 million in Q2 and 8.7 million shares for $1.5 billion year-to-date, and raised its quarterly dividend 10% to $0.990 per share.
Marsh & McLennan Companies entered into a new Amended and Restated 5 Year Credit Agreement providing a multi-currency, unsecured $4.25 billion five-year revolving credit facility. The interest rate is based on Term SOFR plus a fixed margin that varies with the company’s credit ratings.
The new facility expires in June 2031 and requires Marsh & McLennan to maintain specified coverage and leverage ratios that are tested quarterly. In connection with this agreement, the company terminated its prior multi-currency unsecured $3.5 billion five-year revolving credit facility dated October 11, 2023.
Marsh & McLennan Companies President and CEO John Q. Doyle reported an option exercise and related share sale. He exercised options to acquire 16,656 shares of Common Stock at $73.195 per share, then sold 16,656 shares at $161.71 per share in an open‑market transaction.
The filing notes that the sale was effected under a pre‑arranged Rule 10b5‑1 trading plan, meaning it was scheduled in advance. After these transactions, Doyle continues to hold over 100,000 shares of Marsh & McLennan stock directly.
Marsh & McLennan Companies director Morton O. Schapiro received an annual equity grant of 1,349.82 restricted stock units. The award, made under the Marsh & McLennan Companies Directors Stock Compensation Plan, is valued at a reference price of $159.28 per unit and converts into common stock on a 1-for-1 basis.
Following this grant, Schapiro directly holds 90,445.40 shares of common stock, including the underlying shares from these units. This is a compensation-related award rather than an open-market purchase or sale.
Marsh & McLennan Companies director Anthony Anderson received an annual equity grant of 1,349.82 restricted stock units. The award was made under the Marsh & McLennan Companies Directors Stock Compensation Plan and is classified as a grant or award acquisition, not an open-market purchase.
The restricted stock units convert into Marsh & McLennan common stock on a 1-for-1 basis, aligning the director’s compensation with future share performance. Following this grant, Anderson holds a total of 17,082.15 units directly, reinforcing his equity stake in the company.
Marsh & McLennan Companies director Deborah C. Hopkins received an annual equity grant under the company’s Directors Stock Compensation Plan. She was awarded 1,349.82 restricted stock units that convert into common stock on a 1-for-1 basis, reflecting a reference price of $159.28 per share. Following this grant, she directly holds 21,414.56 shares-equivalent of common stock. This is a compensation-related award, not an open-market purchase or sale.
Marsh & McLennan Companies director Tamara Ingram received an annual stock award in the form of 1,349.82 restricted stock units under the company’s Directors Stock Compensation Plan. These units convert into common stock on a 1-for-1 basis.
After this grant, Ingram directly holds 9,086.35 shares-related units, reflecting routine, compensation-based equity rather than an open-market purchase or sale.